{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:53:51Z","timestamp":1792263231603,"version":"4.4.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaccao.2026.02.004","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:20:11Z","timestamp":1776799211000},"page":"120-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Disease Prognosis and Progression in Transthyretin Amyloidosis"],"prefix":"10.1016","volume":"8","author":[{"given":"Joban","family":"Vaishnav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Bampatsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Boursiquot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy","family":"Brailovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3799-9757","authenticated-orcid":false,"given":"Jamie","family":"Zigterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Garcia","family":"Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chafic","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-7464","authenticated-orcid":false,"given":"Jan M.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2026.02.004_bib1","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.02.004_bib2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.02.004_bib3","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.02.004_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.02.004_bib5","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.02.004_bib6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cardfail.2024.06.003","article-title":"Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"31","author":"Garcia-Pavia","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jaccao.2026.02.004_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.009637","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jaccao.2026.02.004_bib8","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jaccao.2024.12.005","article-title":"A multicenter study of contemporary long-term tafamidis outcomes in transthyretin amyloid cardiomyopathy","volume":"7","author":"Masri","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib9","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib10","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2026.02.004_bib11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jchf.2021.06.007","article-title":"Spironolactone in patients with an echocardiographic hfpef phenotype suggestive of cardiac amyloidosis","volume":"9","author":"Sperry","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jaccao.2026.02.004_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib13","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1002\/ehf2.14793","article-title":"Phenotype and prognostic factors in geriatric and non-geriatric patients with transthyretin cardiomyopathy","volume":"11","author":"Volpentesta","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jaccao.2026.02.004_bib14","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1073\/pnas.0400062101","article-title":"Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture","volume":"101","author":"Reixach","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaccao.2026.02.004_bib15","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2026.02.004_bib16","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.jacc.2025.03.477","article-title":"Impact of heart failure severity on vutrisiran efficacy in transthyretin amyloidosis with cardiomyopathy","volume":"85","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/13506129.2025.2570095","article-title":"A comparison of single versus combination mechanism treatment for transthyretin amyloid cardiomyopathy","volume":"33","author":"Gupta","year":"2026","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2026.02.004_bib18","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2026.02.004_bib19","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib20","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib21","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20140155","article-title":"Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage","volume":"35","author":"Manral","year":"2015","journal-title":"Biosci Rep"},{"key":"10.1016\/j.jaccao.2026.02.004_bib22","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1021\/bi301313b","article-title":"Age-related oxidative modifications of transthyretin modulate its amyloidogenicity","volume":"52","author":"Zhao","year":"2013","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.jaccao.2026.02.004_bib23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jacc.2025.09.004","article-title":"Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance","volume":"87","author":"Writing Committee","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib24","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaccao.2026.02.004_bib25","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib26","doi-asserted-by":"crossref","unstructured":"Nies RJ, Ney S, Nies JF, et al. Outpatient diuretic intensification: a simple prognostic marker in cardiac transthyretin amyloidosis. Clin Res Cardiol. Published online March 4, 2025. https:\/\/doi.org\/10.1007\/s00392-025-02617-4.","DOI":"10.1007\/s00392-025-02617-4"},{"issue":"12","key":"10.1016\/j.jaccao.2026.02.004_bib27","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/ejhf.3540","article-title":"Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy","volume":"27","author":"Zeldin","year":"2025","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"10.1016\/j.jaccao.2026.02.004_bib28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/heartjnl-2024-324826","article-title":"Cardiac disease monitoring measures in patients with transthyretin amyloid cardiomyopathy treated with tafamidis","volume":"111","author":"Bampatsias","year":"2025","journal-title":"Heart"},{"key":"10.1016\/j.jaccao.2026.02.004_bib29","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jacc.2024.11.015","article-title":"Outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial","volume":"85","author":"Fontana","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib30","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jaccao.2020.10.007","article-title":"Amyloidosis and 30-day outcomes among patients with heart failure","volume":"2","author":"Arora","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.amjcard.2021.02.035","article-title":"Causes of cardiovascular hospitalization and death in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT])","volume":"148","author":"Miller","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib32","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","article-title":"Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy","volume":"85","author":"Judge","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib33","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.02.004_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.05.015","article-title":"Transthyretin serum levels and clinical outcomes in patients with transthyretin amyloid cardiomyopathy","volume":"142","author":"Minervini","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaccao.2026.02.004_bib35","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.jacc.2025.03.542","article-title":"Early increase in serum transthyretin by acoramidis independently predicts improved survival in TTR amyloid cardiomyopathy","volume":"85","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib36","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1164\/rccm.201007-1179OC","article-title":"Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference","volume":"183","author":"Bois","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaccao.2026.02.004_bib37","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0002-9149(01)01975-0","article-title":"Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy","volume":"88","author":"Shah","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jacc.2024.04.011","article-title":"Prognostic value of a 6-minute walk test in patients with transthyretin cardiac amyloidosis","volume":"84","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib39","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/01.CIR.83.3.778","article-title":"Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure","volume":"83","author":"Mancini","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.02.004_bib40","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/01.CIR.103.7.967","article-title":"Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis","volume":"103","author":"Ponikowski","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.02.004_bib41","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.clml.2021.03.015","article-title":"Cardiopulmonary exercise testing in patients with cardiac amyloidosis","volume":"21","author":"Bhutani","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jaccao.2026.02.004_bib42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jamacardio.2024.0022","article-title":"Cardiopulmonary exercise testing in evaluating transthyretin amyloidosis","volume":"9","author":"Patel","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib43","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jchf.2025.01.020","article-title":"Cardiopulmonary exercise testing with exercise echocardiography to assess treatment response in transthyretin amyloid cardiomyopathy","volume":"13","author":"Patel","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jaccao.2026.02.004_bib44","article-title":"Article commentary: patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs)","volume":"6","author":"Weldring","year":"2013","journal-title":"Health Serv Insights"},{"key":"10.1016\/j.jaccao.2026.02.004_bib45","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.amjcard.2020.10.066","article-title":"Impact of tafamidis on health-related quality of life in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)","volume":"141","author":"Hanna","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib46","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/ehf2.13541","article-title":"Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT","volume":"8","author":"Nativi-Nicolau","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"suppl","key":"10.1016\/j.jaccao.2026.02.004_bib47","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0735-1097(25)01663-8","article-title":"Worsening Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OS) is independently associated with increased risk of adverse outcomes in transthyretin cardiac amyloidosis (ATTR-CA)","volume":"85","author":"Levy","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"114","key":"10.1016\/j.jaccao.2026.02.004_bib48","first-page":"1089","article-title":"Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis","volume":"4","author":"Cyrille","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib49","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaccao.2022.08.007","article-title":"Low QRS voltages in cardiac amyloidosis","volume":"4","author":"Cipriani","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib50","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ijcard.2016.04.030","article-title":"Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings","volume":"214","author":"Sperry","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib51","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/ehf2.14684","article-title":"Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis","volume":"12","author":"Argir\u00f2","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jaccao.2026.02.004_bib52","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2026.02.004_bib53","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib54","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jaccao.2024.03.007","article-title":"Atrial fibrillation as a prognostic factor for all-cause mortality in patients with transthyretin amyloid cardiomyopathy","volume":"6","author":"Witteles","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib55","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/ejhf.2606","article-title":"Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis","volume":"24","author":"Chacko","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaccao.2026.02.004_bib56","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/ehjci\/jead318","article-title":"Evolution and prognostic value of left ventricular deformation and myocardial work parameters in transthyretin amyloid cardiomyopathy","volume":"25","author":"Antonelli","year":"2024","journal-title":"Eur Heart J. Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2026.02.004_bib57","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13506129.2022.2131385","article-title":"Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy","volume":"30","author":"Rettl","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2026.02.004_bib58","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur Heart J. Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2026.02.004_bib59","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy","volume":"23","author":"Rettl","year":"2022","journal-title":"Eur Heart J. Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2026.02.004_bib60","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1038\/s41591-025-03851-z","article-title":"Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial","volume":"31","author":"Jering","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2026.02.004_bib61","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1161\/CIRCULATIONAHA.125.077304","article-title":"Coramitug, a humanized monoclonal antibody for the treatment of transthyretin amyloid cardiomyopathy: a phase 2, randomized, multicenter, double-blind, placebo-controlled trial","volume":"153","author":"Fontana","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.02.004_bib62","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib63","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/ehf2.14815","article-title":"Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy","volume":"11","author":"Dobner","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jaccao.2026.02.004_bib64","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2026.02.004_bib65","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Writing Committee","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2026.02.004_bib67","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.02.004_bib68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.02.004_bib69","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jaccao.2026.02.004_bib70","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/13506129.2016.1207163","article-title":"Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy","volume":"23","author":"Waddington Cruz","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2026.02.004_bib71","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2017.1301419","article-title":"Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial","volume":"24","author":"Keohane","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2026.02.004_bib72","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mus.28026","article-title":"Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: recommendations from a panel of experts","volume":"69","author":"Karam","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jaccao.2026.02.004_bib73","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/mus.28299","article-title":"Estimating meaningful differences in measures of neuropathic impairment, health-related quality of life, and nutritional status in patients with hereditary transthyretin amyloidosis","volume":"71","author":"Folkvaljon","year":"2025","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jaccao.2026.02.004_bib74","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/13506129.2020.1815696","article-title":"Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis","volume":"28","author":"Louwsma","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2026.02.004_bib75","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/13506129.2024.2327342","article-title":"Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis","volume":"31","author":"Berends","year":"2024","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2026.02.004_bib76","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1007\/s10072-024-07562-0","article-title":"Serum neurofilament light chain levels correlate with small fiber related parameters in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN)","volume":"45","author":"Galosi","year":"2024","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jaccao.2026.02.004_bib77","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney","volume":"7","author":"Lobato","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib78","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ejhf.3094","article-title":"Albuminuria in transthyretin cardiac amyloidosis: prevalence, progression and prognostic importance","volume":"26","author":"Ioannou","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaccao.2026.02.004_bib79","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamacardio.2024.4578","article-title":"Kidney outcomes in transthyretin amyloid cardiomyopathy","volume":"10","author":"Ioannou","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib80","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaccao.2024.02.007","article-title":"Effect of tafamidis on renal function in patients with transthyretin amyloid cardiomyopathy in ATTR-ACT","volume":"6","author":"Sperry","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib81","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033094","article-title":"Multiorgan dysfunction and associated prognosis in transthyretin cardiac amyloidosis","volume":"13","author":"Ioannou","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2026.02.004_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.06.009","article-title":"Gamma-glutamyltransferase independently predicts mortality and heart failure hospitalization in cardiac transthyretin amyloidosis","volume":"140","author":"Aimo","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaccao.2026.02.004_bib83","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1586\/egh.09.59","article-title":"Amyloid and the GI tract","volume":"3","author":"Sattianayagam","year":"2009","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jaccao.2026.02.004_bib84","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2796.1994.tb01106.x","article-title":"Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy","volume":"235","author":"Suhr","year":"1994","journal-title":"J Intern Med"},{"key":"10.1016\/j.jaccao.2026.02.004_bib85","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1111\/j.1600-6143.2007.01969.x","article-title":"Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years","volume":"7","author":"Yamamoto","year":"2007","journal-title":"Am J Transplant"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087326000542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087326000542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:32:49Z","timestamp":1788309169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087326000542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666087326000542"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2026.02.004","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease Prognosis and Progression in Transthyretin Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2026.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}